Drug Trial Radar · NCT04632108
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
199
Actual
Start
Jan 28, 2021
Primary completion
Oct 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Aosaikang Biopharmaceutical Co., Ltd
- First posted
- Nov 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.
Conditions
- Malignant Solid Tumor
Interventions
ASKB589 InjectionDrug
ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with serious adverse events (SAE) as assessed by CTCAE v5.0Time frame: up to 21 days following last dose
- The incidence and case number of DLT (Dose Limiting Toxicity) during observation periodTime frame: up to 21 or 28 days following first dose
- Number of participants with adverse events as assessed by CTCAE v5.0Time frame: up to 21 days following last dose
- Maximum Tolerated Dose (MTD)Time frame: up to 21 or 28 days following first dose
- The recommended doseTime frame: from date of treatment start until data cut-off, up to 2 years
- Objective response rateTime frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing cancer hospital
Beijing, Beijing Municipality, China
Linyi cancer hospital
Linyi, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.